Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 4Unknown 3Terminated 3Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell 9Lymphoma, Non-Hodgkin 7Recurrence 6Multiple Myeloma 4Leukemia, Myeloid, Acute 4Lymphoma, Mantle-Cell 3Lymphoma 3Burkitt Lymphoma 3Lymphoma, Follicular 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Resistant Ovarian Carcinoma 1Plasmacytoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Lymphoma, B-Cell, Marginal Zone 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Immunotherapy, Adoptive × Clear all
NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05521802 2023-03-24

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Shanghai AbelZeta Ltd.

Phase 1/2 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡